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Abstract: Transferrin receptor 1 (CD71) is a transmembrane glycoprotein responsible for cellular iron uptake.
Higher expression of CD71 has been identified as a negative prognostic marker for numerous solid tumor types
and for some lymphomas. The aim of this study was to evaluate CD71 expression on acute lymphoblastic leuke-
mia (ALL) cells and to follow its possible clinical correlations. Sixty one patients, aged 1–17 years and diagnosed
with ALL, were enrolled in the study. CD71 expression was analyzed on the bone marrow blastic cells by flow
cytometry. CD71 expression on the leukemic blasts was diversified; in most patients, all blastic cells showed
expression of CD71, but levels of expression varied. CD71 expression was statistically higher on T-lineage leuke-
mias. Within the B lineage ALL, a significant difference in CD71 expression existed between precursor B ALL
and mature B-ALL, which showed higher CD71 expression. CD71 expression positively correlated with Hgb
concentration at diagnosis. Initial risk group assessment and therapy response were not correlated with CD71
expression, although disease free and overall survival times tended to be shorter in patients with B-lineage
leukemias with initial high CD71 expression. (Folia Histochemica et Cytobiologica 2012, Vol. 50, No. 2, 304–311)
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Introduction
The transferrin receptor 1 (TfR1), designated CD71,
is a type II transmembrane homodimeric glycopro-
tein (180 kDa) responsible mainly for cellular iron
uptake via internalization of iron loaded transferrin
[1, 2]. This makes iron available for heme synthesis
and for many metabolic processes necessary for cell
growth and proliferation, including DNA synthesis,
electron transport, nitrogen fixation and oxygen
sensing [1, 2].
CD71 is expressed at high levels on cells with high
iron demand, such as maturing erythroid cells and pla-
cental trophoblast cells, and on cells with a high prolif-
eration rate, such as cells of the basal epidermis and
intestinal epithelium [2–4]. Activated peripheral blood
mononuclear cells express high levels of TfR [2]. This
may be attributable to the increased need for iron as
a cofactor of ribonucleotide reductase, which activity
supplies substrates for DNA synthesis [5]. CD71 over-
expression has been reported in many neoplasms, in-
cluding solid tumors such as lung [6, 7], bladder [8], co-
lon [9], pancreas [10] and breast cancer [11, 12], gliom-
as [13] as well as hematological malignancies [5, 14–16].
Higher expression of CD71 has been identified as a neg-
ative prognostic marker for numerous solid tumor types
[10, 12] as well as for non-Hodgkin’s lymphoma [4, 17,
18]. Antibodies targeting CD71 have been introduced
as an experimental adjuvant anticancer therapy [19].
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There is still very little information on the possi-
ble importance of CD71 in childhood acute lympho-
blastic leukemias (ALL), and the data that is avail-
able is conflicting [17, 20, 21].
The aim of this study was to evaluate CD71 ex-
pression on acute lymphoblastic leukemia cells and
to follow its possible clinical correlations.
Material and methods
Patients. Sixty one patients diagnosed with ALL in the De-
partment of Pediatrics, Hematology, Oncology and Endo-
crinology, Medical University of Gdansk, from whom a sur-
plus bone marrow (BM) was available after the diagnostic
biopsy, were enrolled into this study between 2005 and 2009.
The only inclusion criteria were diagnosis of acute lympho-
blastic leukemia and material availability.
There were 27 girls and 34 boys, median age 5.3 years
(from 1 to 17.6 years); with no significant differences be-
tween the genders. The bone marrows were routinely as-
sessed by the hematological diagnostic laboratory and the
leukemic blasts were classified according to their morphol-
ogy (following French-American-British classification:
L1–L3) and immunophenotype.
55 patients were diagnosed with B-lineage ALL, five pa-
tients had T-lineage ALL, and one patient biphenotypic
T/B ALL. Immunophenotyping: 45 (74%) patients had com-
mon ALL, three (5%) proB, three (5%) prepreB, two (3%)
preB, two (3%) mature B-ALL, four (6.5%) T-cell ALL,
and one (1.5%) preT ALL.
All BMs were cultured in order to obtain karyotype; chro-
mosomes were obtained in 38 patients (62%) and 29 were
found to have chromosomal abnormalities, including 17 cases
of hyperdiploidy and 12 cases of structural abnormalities.
Bcr-abl mutation was investigated by fluorescence in-situ hy-
bridization (FISH) in 49 patients, and was found positive in three.
Clinical data was retrospectively obtained from the rou-
tine clinical evaluations. Risk group qualification was based
on the ALLIC 2000 criteria and was performed after 33 days
of treatment. Patients were categorized as standard (SR),
intermediate (IR), or high risk (HR). Patients who had died
before the risk group assessment were, for the purposes of
statistical analyses, allotted to the high risk group.
Organ involvement. Central nervous system involvement
was defined as a presence of blastic cells in the cerebrospi-
nal fluid, infiltration observed in the magnetic resonance
imaging (MRI) scan, or clinical features of the cranial nerves
involvement. Liver and spleen enlargement were clinically
defined as organ margin palpable more than 1 cm below
the appropriate costal margin.
Hematological abnormalities. Initial peripheral blood (PB)
morphology was routinely evaluated with a Sysmex XE 2100
analyzer. White blood cell (WBC), hemoglobin (Hgb) and
platelet (PLT) count were analyzed. Hyperleukocytosis was
defined as PB white blood cell count (WBC) > 50,000/µl.
Biochemistry. Initial PB serum uric acid (UA) and lactic
dehydrogenase (LDH) were measured.
Treatment response. Treatment response was evaluated
according to the ALLIC 2000 protocol: initial steroid re-
sponse was evaluated based on the absolute count of blas-
tic cells per µl in the PB on the 8th day of the treatment
protocol (Day 8 blastosis). Induction therapy response
was assessed by microscopic analysis of the bone marrow
specimens collected on the 15th and 33rd days of the che-
motherapy protocol (respectively Day 15 BM and Day
33 BM). Remission pattern was denoted M1 (< 5% blasts
cells in the BM, complete remission), M2 (5–25% blast
cells, partial remission), or M3 (> 25% blast cells, no
remission).
Disease-free survival (DFS) and overall survival (OS). DFS
was defined as survival without leukemia relapse; for OS,
deaths from all causes were included. All clinical evalua-
tions are summarized in Figure 1.
Sample preparation. BM was obtained by aspiration biopsy;
preservative free heparin was used as an anticoagulant. All
biopsies were performed prior to treatment implementation.
Bone marrow was first immunophenotyped to select mark-
ers for further blastic cells’ staining. Mononuclear cells were
isolated by density gradient centrifugation on Histopaque
1077 (Sigma–Aldrich). Interphase cells were collected and
washed twice in RPMI medium (Sigma–Aldrich). Aliquots
of 0.3 × 106 cells/50 µl were used for further staining. From
the separation onwards, all staining/washing steps were per-
formed at 4°C.
Antigen expression. CD71 surface expression was mea-
sured on bone marrow blastic cells. Staining to identify
blastic cells (either CD19/CD10 or CD19/CD34 for
B-lineage ALLs or CD7/CD34 for T-lineage ALLs) was
chosen based on the routine bone marrow immunophe-
notyping performed for diagnostic purposes. The percent-
age of blastic cells in our bone marrow samples varied
from 45% to 100% with a median of 90%. Bone marrow
mononuclear cells were stained with the following anti-
body conjugates: anti-CD71 FITC/anti-CD19 (or
anti-CD10) PE/anti-CD34 (or anti-CD19) PE-Cy5 or
anti-CD71 FITC/anti-CD7 PE/anti-CD34 PE-Cy5 (all
antibodies were from BD Bioscience). 5 µl of each mon-
oclonal antibody was added to the appropriate tubes and
incubated for 30 min. Finally, the cells were washed and
analyzed by flow cytometry. Each sample was run with
an appropriate isotype control.
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Figure 1. Schematic representation of the clinical evaluations performed in the study. CD71 flow cytometric measurement
was performed at diagnosis, before treatment implementation
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Figure 2. Examples of CD71 expression. Left panel: low CD71 expression on B-lineage ALL blasts. Right panel:
high CD71 expression on T-lineage ALL. Isotypes are shown with dotted lines and anti-CD71 with solid lines
Flow cytometry analysis. Samples were analyzed by flow
cytometry using a Becton Dickinson FACScan instrument
equipped with a 488-nm argon laser. Five data parameters
were assessed: linear forward and side scatter (FSC, SSC),
FL-1(FITC), FL-2(PE) and FL-3 (PE-Cy5). CellQuest
(Becton Dickinson) and FlowJo (ThreeStar) softwares were
used for data analysis. Mean fluorescence intensity (MFI)
was used as a measure of antigen surface expression. For
individual samples, an anti-CD71 FITC dMFI was calculat-
ed: dMFI = MFI of the population of interest – MFI of the
appropriate isotype control (Figure 2). MFI is expressed in
arbitrary values.
Statistical analysis. Statistica 8.0 PL (StatSoft) software was
used for all of the analyses. The statistical significance of
the results was analyzed by means of Mann–Whitney U test
and Kolmogorow–Smirnoff. Spearman rank test was used
to assess the correlation between the variables. Differences
were considered of statistical significance if the p value was
< 0.05. Disease free survival time and overall survival time
measured from diagnosis were estimated according to the
method of Kaplan–Meier and compared between groups
by means of log-rank test.
The study was approved by the Local Ethics Commit-
tee; the patients and/or their parents (legal guardians) gave
informed consent to participate in the study.
Results
CD 71 expression found on the leukemic blasts was
diversified. In 56/61 patients (92%), all blastic cells
showed expression of CD71 with dMFI median of 13
(ranging from 2 to 284), in four cases CD71 was found
on a subpopulation of 17–24% blasts, only one leu-
kaemia did not show expression of CD71 (Figure 2).
CD71 expression did not differ between sexes —
dMFI median 10.6 for girls and dMFI median 15.6
for boys, nor did it show a correlation with patient
age (Rs = 0.023).
Immunophenotype
CD71 expression was statistically higher on T-lineage
leukemias, with dMFI median for B-lineage ALL of
12.4 (range 2–100) and 27.9 for T-lineage ALLs (range
14–284) (p = 0.01) (Figure 3).
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Within the T-lineage group, the lowest MFI was
noted in the only pre-T leukemia, while T-ALLs all
showed higher MFIs. Within the B-lineage group, the
highest MFI was seen on the mature B and proB blas-
tic cells.
Within the B lineage ALL, a significant difference
in CD71 expression existed between precursor B ALL
and mature B-ALL showing higher CD71 expression
levels (p = 0.02) (Figure 4).
Chromosomal abnormalities
The presence of chromosomal abnormalities did not
correlate with CD71 expression. Patients with chro-
mosomal aberrations showed median CD71 expres-
sion of 15 (range 2–118) vs. 15.9 (range 6–284) in
patients with normal karyotype of the leukemic blasts
(p = 0.49). Hyperdiploidy was also not related to
CD71 expression (median 10.5 in the hyperdiploidy
group vs. 15.9 in non-hyperdiploid blasts; p = 0.23),
nor was bcr-abl presence (32.1 vs. 13.6; p = 0.17).
Initial laboratory and clinical parameters;
initial organ involvement
Patients with initial hyperleukocytosis (n = 11)
showed markedly higher CD71 expression on the blas-
tic cells with median dMFI = 25.7 compared to the
non-hyperleukocytosis patients (n = 50) with dMFI =
= 11.8 (p = 0.007336), although it was due to the
prevalence of hyperleukocytosis in T-lineage leuke-
mias. When only B-lineage ALLs were analyzed, the
difference, although present (dMFI = 11.5 for pa-
tients with hyperleukocytosis [n = 6] and 15.4 for the
remaining patients), was not statistically significant
(p = 0.26).
dMFI CD71 positively correlated with Hgb con-
centration at diagnosis (Rs = 0.31), PLT count
Figure 3. CD71 expression on the leukemic blasts assessed
based on dMFI of anti-CD71 staining. Horizontal lines
indicate median values (p < 0.05)
Figure 4. CD71 expression on B-lineage leukemic blasts
assessed based on dMFI of anti-CD71 staining. Horizontal
lines indicate median values
Figure 5. Correlation between peripheral blood hemoglo-
bin concentrations (PB Hgb) and blastic CD71 expression
in a group of patients with anti-CD71 MFI < 35
(n = 53, Rs = 0.38)
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(Rs = 0.35) and with UA (Rs = 0.30) and LDH (Rs =
= 0.26) concentrations. Correlation with Hgb was
stronger in the group of ALLs with lower CD71 ex-
pression (dMFI < 35, n = 53) (Figure 5).
CD71 expression on the blastic cells did not differ
between patients with extramedullary organ involve-
ment (Table 1).
Therapy response and risk groups
CD71 expression did not differ statistically between the
clinically evaluated risk groups. Therapy response was
assessed based on several parameters: initial response
to the steroid therapy expressed as a PB blastosis on the
8th day of treatment, bone marrow analysis on the 15th
and 33rd day of treatment. None of these parameters
showed correlation with CD71 expression (Table 2).
Disease-free survival (DFS) and overall survival (OS)
There were no relapses or deaths in the T-lineage ALL
groups. The B-lineage group was divided into two
groups based on the MFI expression — MFI < me-
dian (i.e. MFI < 13) and MFI > median (MFI > 13).
The 5 year DFS and 5 year OS probabilities were low-
er in the MFI > 13 group (DFS 0.64 vs. 0.91, Figure 6
and OS 0.81 vs. 0.97, Figure 7) The mortality rate in
the B-lineage ALL with CD71 MFI < 13 was 4%
(1/25), while in the MFI > 13 group 20% (4/20) pa-
tients had died by the end of the observation time.
Discussion
In normal human tissues, CD71 is found predomi-
nantly in the basal epidermis, endocrine pancreas,
hepatocytes, Kupffer cells, testes, and the pituitary
Table 1. Median MFI for anti-CD71 FITC staining (min–max) in groups with or without organ involvement
Organ involvement CNS3 CNS1 p
CNS
Median MFI (min–max) 13 (2–283) 13.6 (5–100)
NS
n 7 52
Hepatomegaly No-hepatomegaly
Liver
Median MFI (min–max) 11.5 (2–118) 14.2 (4–283)
NS
n 33 24
Splenomegaly No-splenomegaly
Spleen
Median MFI (min–max) 16.5 (2–118) 11.9 (4–283)
NS
n 28 29
Table 2. Median MFI for anti-CD71 FITC staining (min–max) depending on the treatment response
                                 > 1,000                               < 1,000 p
8 day blastosis
Median MFI (min–max)                             12.9 (7–283)                                  11.8 (2–92)
NS
n                                 8                                   46
M1 M2 M3 Aplasia
15 day BM
Median MFI (min–max) 10.6 (4–33) 18.9 (6–92) 12.9 (2–283) 13.6 (4–64)
NS
n 19 7 10 19
M1 M2 M3 Aplasia
33 day BM
Median MFI (min–max) 13.02 (2–283) 32 11.2 (4–23)
NS
n 41 0 1 12
Figure 6. Kaplan–Meier curves presenting DFS in groups
of B-lineage-ALL patients with phenotype: CD71 MFI < 13
(continuous line) and CD71 MFI > 13 (dotted line)
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gland; it has also been detected on activated lympho-
cytes, natural killer cells, monocytes and macrophag-
es [15, 22–25]. In hematopoiesis, CD71 is not present
on a pluripotent stem cell, next it is detectable on
erythroid progenitors, and again it is not detected on
mature cells of the erythroid line [26]. Myeloid line
bone marrow precursors are variably CD71 positive:
dividing cells on the level of blast to myelocytes are
all CD71 positive, while non-dividing late precursors
(from metamyelocytes) are predominantly CD71 neg-
ative [26–28]. Quiescent PB lymphocytes, of  both
T and B lineages, lack CD71 which is produced in
them after stimulation [2].
In contrast to a limited pattern of expression in
normal tissues, CD71 is reported to be widely present
on neoplastic cells [2, 15]. Yeh et al. found increased
transferrin binding in peripheral blood mononuclear
cells from patients with leukemia, lymphoma and
myeloma [29]. In B-cell chronic lymphocytic leuke-
mia, CD71 expression is heterogenous, with some
cases showing high expression [30–32]. Both B and
T lineage non-Hodgkin’s lymphomas have been re-
ported to express CD71, with the expression level cor-
relating with the lymphoma grading, though not with
patient survival [18, 33]. Transferrin receptor is over-
expressed in adult T-cell leukemia, a neoplasm relat-
ed to human T-lymphotropic virus type 1 (HTLV-1)
with a poor prognosis [34, 35]. It is also overexpressed
in acute myeloid leukemia [14]. Investigation of CD71
expression and importance, although ongoing in many
adult malignancies, did not draw much attention in
childhood leukemias.
ALL in children has thus far been evaluated in
terms of CD71 expression by two authors only [21,
17]. Koehler et al. investigated CD71 expression in
childhood ALL by flow cytometric immunophenotyp-
ing, and found that 92% of T-lineage ALLs and 32%
of B-lineage ALLs were CD71 positive [21]. Das
Gupta et al. performed an immunohistochemical
study of CD71 in ALLs and showed 62% of T-lineage
ALLs were CD71 positive, compared to 10.9% of
positive common ALLs [17]. One more paper ad-
dressed CD71 expression in ex vivo ALL specimens
from adults [20]. Glasova et al. reported CD71 ex-
pression on a few common ALLs with less than 10%
of positive cells in the PB. Ten cases of T-ALL ana-
lyzed in this study showed a higher percentage of
CD71 positive cells: from 13% to 75% [20].
Our study showed CD71 is present on blastic cells
of almost all ALL cases, the expression being uniform
within one case but significantly varied between cas-
es. T-lineage ALLs showed higher CD71 expression
than B-lineage leukemias, which is in concordance
with the previously published data. Surface CD71
expression has been proven to be a downstream mark-
er of Notch mediated PDK1 activation [20, 36, 37]
and further proposed as a downstream marker of
mTOR activity [38]. It seems that activity of survival
pathway PI3K/PDK1/Akt/mTOR is linked with CD71
expression. In this context, high expression of CD71
on T-cell malignancies is not surprising as the impor-
tance of Notch signaling for T cell development has
been well established [37]. Gain of function mutations
of NOTCH [39, 40] as well as inactivating mutations
of the suppressor PTEN and increased activity of
PI3K/Akt pathway have been frequently identified in
T cell ALL [41].
We demonstrated CD71 expression on most
B-lineage ALLs including common ALL. Other authors
report low frequency of CD71 positives in common
ALL. This discrepancy could be explained by a dif-
ferent analysis approach whereby leukemias were clas-
sified as CD71 positive or negative only. Analysis of
mean florescence intensity of CD71 staining on blas-
tic cells allowed for identification of patients express-
ing smaller amounts of TfR1, which would be exclud-
ed by standard positive-negative analysis (Figure 2)
[42]. Analysis of CD71 as a quantitative feature re-
veals more correlations with clinical data, such as Hgb
and PLT. Like Das Gupta et al., we also found corre-
lation of CD71 with initial hyperleukocytosis, but it
was due to high frequency of hyperleukocytosis in
T-lineage ALLs. The group analyzed by Das Gupta
contained a relatively higher proportion of T-ALL
cases, which is characteristic for the Indian subconti-
nent. The involvement of Notch and PI3K/Akt signal-
ing in the development of some B-lineage acute lym-
phoblastic leukemia cases is emerging in the literature
[39, 40, 43]. Diversity of CD71 expression among lym-
phoblastic leukemias originating from the B-lineage
observed in this study might indicate different levels
of PI3K/Akt/mTOR pathway activity in this group [44].
Figure 7. Kaplan–Meier curves presenting OS in groups of
B-lineage-ALL patients with phenotype: CD71 MFI < 13
(continuous line) and CD71 MFI > 13 (dotted line)
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We also attempted an analysis of CD71 putative
prognostic value in precursor-B ALL and found less
favorable outcomes in patients with higher CD71 ex-
pression. Though the observation did not reach sta-
tistical significance, taking into account a relatively
small number of events in our group and a short time
of the follow-up, it seems noteworthy. Kohler et al.
showed no relation between CD71 positivity and the
EFS in a large group of patients. It is difficult to com-
pare our data with Koehler’s, as two decades ago EFS
oscillated around 70% after three years, while in our
material in the low CD71 group it exceeds 90% in
a five-year perspective. Different protocols, improved
supportive therapy, and improved outcomes of bone
marrow transplantations have improved survival rates
in all centers, making direct comparisons between old
and new data impossible. Our group consisted of all
the patients with ALL from whom bone marrow spec-
imens were available over a period of four years in
a single center with the same treatment protocol.
The number of events noted allowed for statistical
EFS and OS analysis only for B-lineage ALLs. We
are continuing the follow-up of the patients includ-
ed in this study.
In recent years, increasing effort has been focused
in pediatric oncology on identifying molecular features
of malignant cells in order to establish new risk fac-
tors, especially in the clinical low risk groups. The role
of TfR1 requires further investigation in this context.
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